002107.SZ SHZ
Shandong Wohua Pharmaceutical Co., Ltd.
1W: -3.3%
1M: +5.8%
3M: +11.8%
YTD: -3.0%
1Y: +2.0%
3Y: +27.8%
5Y: +2.3%
¥7.09 ($1.06)
-0.01 (-0.14%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$817M
+7.0% ▲
5Y CAGR: -4.1%
Gross Profit
$614M
+11.0% ▲
5Y CAGR: -4.8%
Operating Income
$104M
+132.4% ▲
5Y CAGR: -14.2%
Net Income
$96M
+162.9% ▲
5Y CAGR: -11.8%
EPS (Diluted)
$0.17
+183.3% ▲
5Y CAGR: -11.3%
EBITDA
$133M
+78.2% ▲
5Y CAGR: -12.2%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $943M | $1.0B | $910M | $764M | $817M |
| YoY Growth | -6.3% | +7.7% | -10.4% | -16.0% | +7.0% |
| Cost of Revenue | $212M | $251M | $232M | $210M | $203M |
| Gross Profit | $730M | $764M | $677M | $554M | $614M |
| Gross Margin | 77.5% | 75.3% | 74.4% | 72.6% | 75.1% |
| R&D Expenses | $47M | $50M | $45M | $41M | $105M |
| SG&A Expenses | $434M | $538M | $567M | $463M | $473M |
| Operating Expenses | $538M | $651M | $621M | $510M | $510M |
| Operating Income | $193M | $112M | $56M | $45M | $104M |
| Operating Margin | 20.4% | 11.1% | 6.2% | 5.8% | 12.7% |
| Interest Expense | $6M | $129K | $129K | $75K | $102K |
| Income Before Tax | $190M | $111M | $55M | $43M | $102M |
| Tax Expense | $29M | $21M | $8M | $9M | $14M |
| Net Income | $163M | $107M | $59M | $36M | $96M |
| Net Margin | 17.3% | 10.6% | 6.5% | 4.8% | 11.7% |
| EPS (Diluted) | $0.28 | $0.19 | $0.10 | $0.06 | $0.17 |
| EBITDA | $225M | $146M | $88M | $75M | $133M |
| Shares Outstanding | 577M | 577M | 588M | 607M | 563M |